237 related articles for article (PubMed ID: 23978089)
21. [Sodium-glucose cotransporter type 2 inhibitors (SGLT2): from familial renal glucosuria to the treatment of type 2 diabetes mellitus].
Pérez López G; González Albarrán O; Cano Megías M
Nefrologia; 2010; 30(6):618-25. PubMed ID: 21113210
[TBL] [Abstract][Full Text] [Related]
22. Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin.
Jabbour SA; Whaley JM; Tirmenstein M; Poucher SM; Reilly TP; Boulton DW; Saye J; List JF; Parikh S
Postgrad Med; 2012 Jul; 124(4):62-73. PubMed ID: 22913895
[TBL] [Abstract][Full Text] [Related]
23. Sodium glucose cotransporter 2 and the diabetic kidney.
Komala MG; Panchapakesan U; Pollock C; Mather A
Curr Opin Nephrol Hypertens; 2013 Jan; 22(1):113-9. PubMed ID: 23042029
[TBL] [Abstract][Full Text] [Related]
24. [New possibility in the oral glucose lowering treatment of type 2 diabetes mellitus: sodium-glucose co-transporter-2 inhibitors].
Simonyi G
Orv Hetil; 2012 May; 153(18):695-701. PubMed ID: 22547464
[TBL] [Abstract][Full Text] [Related]
25. Sodium-glucose cotransporter 2 inhibitors: the new option for diabetes mellitus management.
Powell J; Miller SA; Taylor JR
South Med J; 2015 Feb; 108(2):82-90. PubMed ID: 25688892
[TBL] [Abstract][Full Text] [Related]
26. A review of the efficacy and safety of canagliflozin in elderly patients with type 2 diabetes.
Elmore LK; Baggett S; Kyle JA; Skelley JW
Consult Pharm; 2014; 29(5):335-46. PubMed ID: 24849690
[TBL] [Abstract][Full Text] [Related]
27. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.
Reed JW
Vasc Health Risk Manag; 2016; 12():393-405. PubMed ID: 27822054
[TBL] [Abstract][Full Text] [Related]
28. Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats.
Nagata T; Fukazawa M; Honda K; Yata T; Kawai M; Yamane M; Murao N; Yamaguchi K; Kato M; Mitsui T; Suzuki Y; Ikeda S; Kawabe Y
Am J Physiol Endocrinol Metab; 2013 Feb; 304(4):E414-23. PubMed ID: 23249697
[TBL] [Abstract][Full Text] [Related]
29. The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury.
Chu C; Lu YP; Yin L; Hocher B
Kidney Blood Press Res; 2019; 44(2):149-157. PubMed ID: 30939483
[TBL] [Abstract][Full Text] [Related]
30. SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment.
Scheen AJ
Expert Opin Drug Saf; 2015; 14(12):1879-904. PubMed ID: 26513131
[TBL] [Abstract][Full Text] [Related]
31. Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations.
Scheen AJ
Expert Opin Drug Metab Toxicol; 2014 May; 10(5):647-63. PubMed ID: 24387329
[TBL] [Abstract][Full Text] [Related]
32. Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?
Gilbert RE
Kidney Int; 2014 Oct; 86(4):693-700. PubMed ID: 24257692
[TBL] [Abstract][Full Text] [Related]
33. Dapagliflozin: a new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes.
Vivian EM
Am J Health Syst Pharm; 2015 Mar; 72(5):361-72. PubMed ID: 25694411
[TBL] [Abstract][Full Text] [Related]
34. [Glycosuria with SGLT-2 inhibitors--a new treatment approach for type 2 diabetes mellitus].
Rosak C; Forst T
MMW Fortschr Med; 2012 Dec; 154 Suppl 4():95-101. PubMed ID: 23326927
[TBL] [Abstract][Full Text] [Related]
35. POTENTIAL PLACE OF SGLT2 INHIBITORS IN TREATMENT PARADIGMS FOR TYPE 2 DIABETES MELLITUS.
Handelsman Y
Endocr Pract; 2015 Sep; 21(9):1054-65. PubMed ID: 26132997
[TBL] [Abstract][Full Text] [Related]
36. Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician.
Dandona P; Chaudhuri A
Int J Clin Pract; 2017 May; 71(5):. PubMed ID: 28440009
[TBL] [Abstract][Full Text] [Related]
37. [Contributions of SGLT-2 and new drugs under investigation].
Mediavilla Bravo JJ
Semergen; 2014 Jul; 40 Suppl 2():34-40. PubMed ID: 25311718
[TBL] [Abstract][Full Text] [Related]
38. [Canagliflozin (Invokana): kidney SGLT2 cotransporter inhibitor for treating type 2 diabetes].
Scheen AJ
Rev Med Liege; 2014 Dec; 69(12):692-9. PubMed ID: 25796788
[TBL] [Abstract][Full Text] [Related]
39. Dapagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes.
Demaris KM; White JR
Drugs Today (Barc); 2013 May; 49(5):289-301. PubMed ID: 23724409
[TBL] [Abstract][Full Text] [Related]
40. Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits.
Lupsa BC; Inzucchi SE
Diabetologia; 2018 Oct; 61(10):2118-2125. PubMed ID: 30132031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
